- Healthcare Acquired Infections Revogene® C. difficile
- Pediatric & Neonatal Revogene® GBS LB
- Respiratory Revogene® SARS-CoV-2 Revogene® Strep A
- Healthcare Acquired Infections Revogene® Carba C
Improves satisfaction among patients and physicians by providing rapid, accurate, actionable results for the detection of Clostridium difficile infection (CDI)
Catalog Number: 410300
Definitive answers, confidence in results
Definitive answers, confidence in results
Support & Documents
Downloadable PDFs
FAQs
Colonization is more common than C. diff infection. The patient exhibits NO clinical symptoms (asymptomatic) but may test positive for the C.diff organism or its toxin gene. With infection, the patient exhibits clinical symptoms and tests positive for the C.diff organism and/or its toxin.
Use a stool toxin test as part of a multi-step algorithm (ie, glutamate dehydrogenase [GDH] plus toxin; GDH plus toxin, arbitrated by nucleic acid amplification test [NAAT]; or NAAT plus toxin) rather than a NAAT alone for all specimens received in the clinical laboratory when there are no pre-agreed institutional criteria for patient stool submission.
Use a NAAT alone or a multi-step algorithm for testing (ie, GDH plus toxin; GDH plus toxin, arbitrated by NAAT; or NAAT plus toxin) rather than a toxin test alone when there are pre-agreed institutional criteria for patient stool submission.
There is insufficient data to recommend the use of biologic markers as an adjunct to diagnosis.
Revogene C. difficile – 87493